Primary Breast Cancer Clinical Trial
Official title:
Comparative Study of Scalp Cooling System and Chemical Cold Cap on Prevention of Chemotherapy-induced Alopecia in Women With Breast Cancer
This is a phase III, single-center, prospective, open-label, randomized,controlled study
To conduct a prospective randomized controlled study comparing the effect of scalp cooling system (DigniCap) and chemical cold cap on preventing chemotherapy-induced alopecia in a group of breast cancer patients receiving standard anthracycline followed paclitaxel regimens. To obtain the exact data on the role of different methods of preventing alopecia in Chinese women with breast cancer. PASS 11 software was used to calculate the sample size. According to the results of previous studies, the hair retention rate of the cold cap group was 67.7%, the hair retention rate of the scalp cooling system group was 50.5%, α=0.05，Power=0.8. The sample size was calculated to be at least 128 cases in each group, 256 cases in total. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05923177 -
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
|
Phase 1 | |
| Completed |
NCT01033162 -
Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care
|
N/A | |
| Recruiting |
NCT03270007 -
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
|
Phase 4 | |
| Completed |
NCT00527449 -
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
|
Phase 2 | |
| Completed |
NCT04468113 -
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
|
||
| Active, not recruiting |
NCT01019616 -
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
|
Phase 3 | |
| Completed |
NCT01314833 -
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
|
Phase 3 | |
| Completed |
NCT04127019 -
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
|
Phase 3 | |
| Terminated |
NCT00172068 -
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
|
Phase 2 | |
| Completed |
NCT01049425 -
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT01840293 -
Breast Cancer Proteomics and Molecular Heterogeneity
|
||
| Completed |
NCT01779479 -
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)
|
Phase 2 | |
| Completed |
NCT04277338 -
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
|
Phase 1 | |
| Recruiting |
NCT05445050 -
mULM to Support Breast Cancer Diagnosis and Therapy
|
N/A | |
| Completed |
NCT00793377 -
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
|
Phase 3 |